A previous report showed the beneficial effect of selective 5-HT2A receptor (5-HT2AR) antagonism against microglial dysfunction and amyloid deposition in the APP/PS1 amyloid model of AD (Lu et al., 2021). Here, APP is linked to Alzheimer disease.